MétaCan
Menu
Back to cohort
Record W4387362770 · doi:10.7554/elife.91645

Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications

2023· article· en· W4387362770 on OpenAlexafffund
Riham Ayoubi, Joël Ryan, Michael Biddle, Walaa Alshafie, Maryam Fotouhi, Sara González Bolívar, Vera Ruíz Moleón, Peter Eckmann, Donovan Worrall, Ian McDowell, Kathleen Southern, Wolfgang Reintsch, Thomas M. Durcan, Claire M. Brown, Anita Bandrowski, Harvinder Virk, A.M. Edwards, Peter S. McPherson, Carl Laflamme

Bibliographic record

VenueeLife · 2023
Typearticle
Languageen
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsUniversity of TorontoMcGill UniversityMontreal Neurological Institute and Hospital
FundersNational Institute of General Medical SciencesNational Institute on AgingCanadian Institutes of Health ResearchGenentechMitacsMotor Neurone Disease AssociationOntario Genomics InstituteGovernment of CanadaMerck KGaAOntario GenomicsGenome CanadaBayerALS Society of CanadaMcGill UniversityEuropean Federation of Pharmaceutical Industries and AssociationsEmory UniversityBristol-Myers SquibbPfizerALS AssociationMichael J. Fox Foundation for Parkinson's Research
KeywordsAntibodyPolyclonal antibodiesProteomeAntibody RepertoireMonoclonal antibodyComputational biologyComputer scienceBiologyImmunologyBioinformatics

Abstract

fetched live from OpenAlex

Antibodies are critical reagents to detect and characterize proteins. It is commonly understood that many commercial antibodies do not recognize their intended targets, but information on the scope of the problem remains largely anecdotal, and as such, feasibility of the goal of at least one potent and specific antibody targeting each protein in a proteome cannot be assessed. Focusing on antibodies for human proteins, we have scaled a standardized characterization approach using parental and knockout cell lines (Laflamme et al., 2019) to assess the performance of 614 commercial antibodies for 65 neuroscience-related proteins. Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners, have demonstrated that: ( i ) more than 50% of all antibodies failed in one or more applications, ( ii ) yet, ~50–75% of the protein set was covered by at least one high-performing antibody, depending on application, suggesting that coverage of human proteins by commercial antibodies is significant; and ( iii ) recombinant antibodies performed better than monoclonal or polyclonal antibodies. The hundreds of underperforming antibodies identified in this study were found to have been used in a large number of published articles, which should raise alarm. Encouragingly, more than half of the underperforming commercial antibodies were reassessed by the manufacturers, and many had alterations to their recommended usage or were removed from the market. This first study helps demonstrate the scale of the antibody specificity problem but also suggests an efficient strategy toward achieving coverage of the human proteome; mine the existing commercial antibody repertoire, and use the data to focus new renewable antibody generation efforts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.320
Threshold uncertainty score0.337

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.450
Teacher spread0.353 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations62
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueeLifeSame topicMonoclonal and Polyclonal Antibodies ResearchFrench-language works237,207